HeartMate 3 LVAD

With Full Maglev Flow Technology

About HeartMate 3 LVAD

The HeartMate​ 3™​ Left Ventricular Assist Device (LVAD) is a mechanical circulatory support device designed for patients with advanced heart failure. With significantly improved outcomes and survival comparable to heart transplant at 2 years1-3  and 5 years,4-7 our LVAD technology is making a better future possible for many patients with advanced heart failure.*1-3 The HeartMate​ 3 LVAD has advanced the field of LVAD therapy and is setting the standard with innovation and outstanding clinical outcomes.1

The Full MagLev Flow Technology within the HeartMate 3 LVAD maintains gentle blood handling to minimize complications and hemocompatibility-related adverse events.

HeartMate 3 LVAD with Full MagLev Flow Technology offers

  • Fully levitated, self-centering rotor, which does not require hydrodynamic or mechanical bearings
  • Large, consistent blood flow pathways, which reduces shear stress8
  • Intrinsic pulsatility, which reduces stasis and minimize thrombus8,9
Cut across view of the HeartMate 3 Maglev Pump
Product details

HeartMate 3 LVAD Product Information

HeartMate 3 LVAD Clinical Evidence

There are comprehensive clinical evidence materials available to learn about the survival rate and patient improvement associated with the HeartMate 3 LVAD. For a deep dive into the clinical data, visit the Clinical Evidence information.

MOMENTUM 3 5-Year Outcomes

MOMENTUM 3 is the largest LVAD trial ever conducted demonstrating excellent survival and safety outcomes with HeartMate 3™ LVAD.**1

HEARTMATE 3™ LVAD, a proven long-term, life-extending therapy for patients with advanced heart failure

Median survival
5 years4

survival at
5 years4

Improved Safety Profile5

The ELEVATE Registry5 evaluated the real-world experience of the HeartMate 3 LVAD in a post-approval setting. 5-year extended follow-up showed:

10.8% in first 2 years
3.6% in years 2-5

1.1% at 5 years

All major event types were reduced in the 2-5 years follow-up period compared to 0-2 years, especially hemocompatiblity-related adverse events.

HeartMate 3 LVAD Education and Training

For the safe and effective management of advanced heart failure with the HeartMate 3 LVAD, we provide comprehensive educational resources. The following resources are designed to help you better understand patient education, use cases, surgical procedure and more.

Manuals & Resources

Manuals & Resources

Customer Service

Customer Service

This device is commercially available for use in select international markets.

*Based on published data from separate datasets, which may involve different patient populations and other variables. Not a head-to-head comparison. Data presented for informational purposes only.
**HeartMate 3 LVAD demonstrated superiority in event-free survival (primary endpoint) in the MOMENTUM 3 trial compared to HeartMate II™ LVAD.
§For a continuous-flow LVAD in a randomized controlled trial.


  1. Mehra M, Uriel N, Naka Y, et al. A Fully Magnetically Levitated Left Ventricular Assist Device-Final Report. N Engl J Med. 2019;380:1618-1627.
  2. Khush KK, Cherikh WS, Chambers DC, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-fifth Adult Heart Transplant Report-2018; Focus Theme: Multiorgan Transplantation. J Heart Lung Transplant. 2018;37:1155-1168.
  3. Teuteberg JJ, Cleveland JC Jr, Cowger J, et al. The Society of Thoracic Surgeons Intermacs 2019 Annual Report: The Changing Landscape of Devices and Indications. Ann Thorac Surg. March 2020;109(3):649-660.
  4. Mehra MR, Goldstein DJ, Cleveland JC, et al. Five-year outcomes in patients with fully magnetically levitated vs axial-flow left ventricular assist devices in the MOMENTUM 3 randomized trial. JAMA. 2022;328(12):1233-1242. doi:10.1001/jama.2022.16197.
  5. Schmitto JD, Shaw S, Garbade J, et al. Long-Term Results in Real World Patients Treated with HeartMate 3 LVAD for Advanced Heart Failure: Data from the ELEVATE Registry. European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting; October 8, 2022; Milan, Italy.
  6. Jorde UP, Saeed O, Koehl D, et al. The Society of Thoracic Surgeons Intermacs 2023 Annual Report: Focus on Magnetically Levitated Devices. Ann Thorac Surg 2024;117(1):33-44. doi:10.1016/j.athoracsur.2023.11.004.
  7. Nayak A, Hall SA, Uriel N, et al. Predictors of 5-Year Mortality in Patients Managed With a Magnetically Levitated Left Ventricular Assist Device. J Am Coll Cardiol 2023;82(9):771-781. doi:10.1016/j.jacc.2023.05.066.
  8. Bourque K, Cotter C, Dague C, et al. Design rationale and preclinical evaluation of the HeartMate 3 Left Ventricular Assist System for hemocompatibility. Am Soc Artificial Int Organs. 2016;62:375-383.
  9. Bourque K, Dague C, Farrar D, et al. In vivo assessment of a rotary left ventricular assist device-induced artificial pulse in the proximal and distal aorta. Artificial Organs. 2006;30:638-642.

MAT-2106243 v2.0